<< Researchers to look at relationship between tinnitus and defects in the inner ear | Arana updates inflammatory pipeline milestones >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | Dansk | Nederlands | Русский

Review of drug delivery market

Published on September 18, 2008 at 7:57 PM · 1 Comment

Combating losses due to patent expiries has become a high priority for pharmaceutical companies. Investing in new drug delivery technologies is becoming a critical strategy for them to maintain a strong presence in this cut-throat market as they offer the potential to enhance the life cycle of established drugs.

A number of drug delivery, pharmaceutical and biotechnology companies are allocating significant resources towards the development of novel drug delivery systems. Once a small market, the drug delivery market is now poised for significant growth and holds great opportunities for both current players and new entrants.

"The global drug delivery market has witnessed encouraging growth in the past and is forecasted to gain significant importance in the coming years," notes Frost & Sullivan Industry Analyst Sylvia Miriyam Findlay. "Heightened competition, the need to maximise revenues and combating patent expiries have forced pharmaceutical companies roll up their sleeves and seek out novel drug delivery systems."

Though the drug delivery market is dominated by oral forms of drugs (52 per cent of the market), other methods, particulary the non-invasive forms - pulmonary, transdermal and nanotechnology - are growing at a rapid pace.

The systemic delivery of drugs through pulmonary means has been the subject of significant research in the medical community. No longer confined to the treatment of respiratory diseases, the successes of dry powder inhalation have pushed the inhalation market to a new level.

Trasndermal drug delivery has also been gaining momentum as certain applications, such as contraceptive patches, have been found to be as effective as their oral counterparts. Cancer pain medication - Fentanyl - has been delivered transdermally and has witnessed increased uptake because of its convenience. Neurological and diabetes medications are other therapeutic drugs that are being investigated for transdermal drug delivery.

One of the most promising areas in drug delivery is nanotechnology. Nano-enabled drug delivery offers tremendous advantages over the current forms of drug delivery such as enhanced solubility, commendable bio-availability, better targeting and controlled delivery.

Comments
  1. huiyi Su huiyi Su People's Republic of China says:

    Under the direction of Professor Roberts, CoEBio3, UK, Guilin Peptide Technology Limited owns a proprietary technology for making polyamino acids of unique quality, economically in commercial scale.



    alpha,gamma-poly(L-glutamic acid)
    Mw 20000-40000(based on viscosity)
    White crystal
    non-cytotoxicity(MTT)
    Purity: 99.9%(HPLC)
    Source: chemically synthetic
    150USD/20g, 1050USD/Kg

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading